Synthesis and pharmacology of conformationally restricted raloxifene analogues: Highly potent selective estrogen receptor modulators

Journal of Medicinal Chemistry

Volumn 41, Issue 8, 1998, Pages 1272-1283

  Grese, Timothy A ^a   Pennington, Lewis D ^a   Sluka, James P ^a   Dee Adrian, M ^a   Cole, Harlan W ^a   Fuson, Tina R ^a   Magee, David E ^a   Lynn Phillips, D ^a   Rowley, Ellen R ^a   Shetler, Pamela K ^a   Short, Lorri L ^a   Venugopalan, Murali ^a   Yang, Na N ^a   Sato, Masahiko ^a   Glasebrook, Andrew L ^a   Bryant, Henry U ^a  

^a ELI LILLY AND COMPANY   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

2,8 DIHYDROXY [4 [2 (1 PIPERIDINYL)ETHOXY]PHENYL] 5H BENZO[B]NAPTHO[2.1 D]PYRAN; ESTROGEN RECEPTOR; LY 357489; RALOXIFENE; RALOXIFENE DERIVATIVE; UNCLASSIFIED DRUG;

ANIMAL EXPERIMENT; ARTICLE; BONE METABOLISM; CELL STRAIN MCF 7; CHOLESTEROL METABOLISM; DRUG CONFORMATION; DRUG EFFECT; DRUG POTENCY; DRUG RECEPTOR BINDING; DRUG SPECIFICITY; DRUG SYNTHESIS; HUMAN; HUMAN CELL; MOUSE; NONHUMAN; OVARIECTOMY; POSTMENOPAUSE OSTEOPOROSIS; RECEPTOR AFFINITY; STRUCTURE ACTIVITY RELATION; TARGET ORGAN; TISSUE SPECIFICITY;

EID: 15144355781     PISSN: 00222623     EISSN: None     Source Type: Journal    
DOI: 10.1021/jm970688z     Document Type: Article

References (60)

1. Lindsay, R. Sex steroids in the pathogenesis and prevention of osteoporosis. In Osteoporosis: Etiology, Diagnosis, and Management; Riggs, B. L., Melton, L. J., Eds.; Raven: New York, 1988; pp 333-358.
2. Ross, R. K.; Pike, M. C.; Mack, T. M.; Henderson, B. E. Oestrogen replacement therapy and cardiovascular disease. In HRT and Osteoporosis; Drife, J. O., Studd, J. W. W., Eds.; Springer-Verlag: London, 1990; pp 209-222.
3. Cust, M. P.; Gangar, K. F.; Whitehead, M. I. Oestrogens and cancer. In HRT and Osteoporosis; Drife, J. O., Studd, J. W. W., Eds.; Springer-Verlag: London, 1990; pp 177-186.
4. Session, D. R.; Kelly, A. C.; Jewelewicz, R. Current concepts in estrogen replacement therapy in the menopause. Fertility Sterility 1993, 2, 277-284 and references therein.
5. (a) Colditz, G. A.; Hankinson, S. E.; Hunter, D. J.; Willett, W. C.; Manson, J. E.; Stampfer, M. J.; Hennekens, C.; Rosner, B.; Speizer, F. E. The use of estrogens and progestins and the risk of breast cancer in postmenopausal women. N. Engl. J. Med. 1995, 332, 1589-1593.
6. (b) Collaborative Group on Hormonal Factors in Breast Cancer. Breast cancer and hormone replacement therapy: Collaborative reanalysis of data from 51 epidemiological studies of 52,705 women with breast cancer and 108,411 women withou breast cancer. Lancet 1997, 350, 1047-1059.
7. Beresford, S. A. A.; Weiss, N. S.; Voigt, L. F.; McKnight, B. Risk of endometrial cancer in relation to use of oestrogen combined with cyclic progestagen therapy in postmenopausal women. Lancet 1997, 349, 458-461.
8. For recent reviews, see: (a) Miquel, J.-F.; Gilbert, J. A chemical classification of nonsteroidal antagonists of sex-steroid hormone action. J. Steroid Biochem. Mol. Biol. 1988, 31, 525-544. (b) Magarian, R. A.; Overacre, L. B.; Singh, S.; Meyer, K. L. The medicinal chemistry of nonsteroidal antiestrogens. Curr. Med. Chem. 1994, 1, 61-104. (c) Chander, S. K.; Sahota, S. S.; Evans, T. R. J.; Luqmani, Y. A. The biological evaluation of novel antioestrogens for the treatment of breast cancer. Crit. Rev. Oncol. Hematol. 1993, 15, 243-269. (d) Jordan, V. C. Alternate antiestrogens and approaches to the prevention of breast cancer. J. Cell Biochem. 1995, 51-57.
9. For recent reviews, see: (a) Miquel, J.-F.; Gilbert, J. A chemical classification of nonsteroidal antagonists of sex-steroid hormone action. J. Steroid Biochem. Mol. Biol. 1988, 31, 525-544. (b) Magarian, R. A.; Overacre, L. B.; Singh, S.; Meyer, K. L. The medicinal chemistry of nonsteroidal antiestrogens. Curr. Med. Chem. 1994, 1, 61-104. (c) Chander, S. K.; Sahota, S. S.; Evans, T. R. J.; Luqmani, Y. A. The biological evaluation of novel antioestrogens for the treatment of breast cancer. Crit. Rev. Oncol. Hematol. 1993, 15, 243-269. (d) Jordan, V. C. Alternate antiestrogens and approaches to the prevention of breast cancer. J. Cell Biochem. 1995, 51-57.
10. For recent reviews, see: (a) Miquel, J.-F.; Gilbert, J. A chemical classification of nonsteroidal antagonists of sex-steroid hormone action. J. Steroid Biochem. Mol. Biol. 1988, 31, 525-544. (b) Magarian, R. A.; Overacre, L. B.; Singh, S.; Meyer, K. L. The medicinal chemistry of nonsteroidal antiestrogens. Curr. Med. Chem. 1994, 1, 61-104. (c) Chander, S. K.; Sahota, S. S.; Evans, T. R. J.; Luqmani, Y. A. The biological evaluation of novel antioestrogens for the treatment of breast cancer. Crit. Rev. Oncol. Hematol. 1993, 15, 243-269. (d) Jordan, V. C. Alternate antiestrogens and approaches to the prevention of breast cancer. J. Cell Biochem. 1995, 51-57.
11. For recent reviews, see: (a) Miquel, J.-F.; Gilbert, J. A chemical classification of nonsteroidal antagonists of sex-steroid hormone action. J. Steroid Biochem. Mol. Biol. 1988, 31, 525-544. (b) Magarian, R. A.; Overacre, L. B.; Singh, S.; Meyer, K. L. The medicinal chemistry of nonsteroidal antiestrogens. Curr. Med. Chem. 1994, 1, 61-104. (c) Chander, S. K.; Sahota, S. S.; Evans, T. R. J.; Luqmani, Y. A. The biological evaluation of novel antioestrogens for the treatment of breast cancer. Crit. Rev. Oncol. Hematol. 1993, 15, 243-269. (d) Jordan, V. C. Alternate antiestrogens and approaches to the prevention of breast cancer. J. Cell Biochem. 1995, 51-57.
12. Jordan, V. C. A current view of tamoxifen for the treatment and prevention of breast cancer. Br. J. Pharmacol. 1993, 110, 507-517.
13. For recent reviews, see: (a) Grese, T. A.; Dodge, J. A. Estrogen receptor modulators: effects in non-traditional target tissues. Annu. Rep. Med. Chem. 1996, 31, 181-190. (b) Kauffman, R. F.; Bryant, H. U. Selective estrogen receptor modulators. Drug News Perspect. 1995, 8, 531-539. (c) Evans, G. L.; Turner, R. T. Tissue-selective actions of estrogen analogs. Bone 1995, 17, 181S-190S.
14. For recent reviews, see: (a) Grese, T. A.; Dodge, J. A. Estrogen receptor modulators: effects in non-traditional target tissues. Annu. Rep. Med. Chem. 1996, 31, 181-190. (b) Kauffman, R. F.; Bryant, H. U. Selective estrogen receptor modulators. Drug News Perspect. 1995, 8, 531-539. (c) Evans, G. L.; Turner, R. T. Tissue-selective actions of estrogen analogs. Bone 1995, 17, 181S-190S.
15. For recent reviews, see: (a) Grese, T. A.; Dodge, J. A. Estrogen receptor modulators: effects in non-traditional target tissues. Annu. Rep. Med. Chem. 1996, 31, 181-190. (b) Kauffman, R. F.; Bryant, H. U. Selective estrogen receptor modulators. Drug News Perspect. 1995, 8, 531-539. (c) Evans, G. L.; Turner, R. T. Tissue-selective actions of estrogen analogs. Bone 1995, 17, 181S-190S.
16. Jones, C. D.; Jevnikar, M. G.; Pike, A. J.; Peters, M. K.; Black, L. J.; Thompson, A. R.; Falcone, J. F.; Clemens, J. A. Antiestrogens. 2. Structure-activity studies in a series of 3-aroyl-2-arylbenzo[b]thiophene derivatives leading to [6-hydroxy-2-(4-hydroxypnenyl)benzo[&]thien-3-yl][4-[2-(l-piperidinyl) ethoxy]phenyllmethanone hydrochloride (LY156758), a remarkably effective estrogen antagonist with only minimal intrinsic estrogenicity. J. Med. Chem. 1984, 27, 1057-1066.
17. (a) Draper, M. W., Flowers, D. E.; Huster, W. J.; Neild, J. A.; Harper, K. D.; Arnaud, C. A controlled trial of raloxifene (LY139481) HCl: Impact on bone turnover and serum lipid profile in healthy postmenopausal women. J. Bone Miner. Res. 1996, 11, 835-842.
18. (b) Delmas, P. D.; Bjarnason, N. H.; Mitlak, B. H.; Ravoux, A.-C.; Shah, A. S.; Huster, W. J.; Draper, M.; Christiansen, C. Effects of raloxifene on bone mineral density, serum cholesterol concentrations, and uterine endometrium in postmenopausal women. N. Engl. J. Med. 1997, 337, 1641.
19. (a) Sato, M.; Rippy, M. K.; Bryant, H. U. Raloxifene, tamoxifen, nafoxidine, or estrogen effects on reproductive and nonreproductive tissues in ovariectomized rats. FASEB J. 1996, 10, 905-912.
20. (b) Black, L. J.; Sato, M.; Rowley, E. R.; Magee, D. E.; Bekele, A.; Williams, D. C.; Cullinan, G. J.; Bendele, R.; Kauffman, R. F.; Bensch, W. R.; Frolik, C. A.; Termine, J. D.; Bryant, H. U. Raloxifene (LY139481 HCl) prevents bone loss and reduces serum cholesterol without causing uterine hypertrophy in ovariectomized rats. J. Clin. Invest. 1994, 93, 63-69.
21. 12,18,34 do not support their findings or conclusions.
22. Gauthier, S.; Caron, B.; Cloutier, J.; Dory, Y. L.; Favre, A/; Larouche, D.; Mailhot, J.; Ouellet, C.; Schwerdtfeger, A.; Leblanc, G.; Martel, C.; Simard, J.; Mérand, Y.; Bélanger, A.; Labrie, C.; Labrie, F. (S)-(+)-4-[7-(2,2-Dimethyl-1-oxopropoxy)-4-methyl-2-[4-[2-(1-piperidinyl)ethoxy] phenyl]-2H-1-benzopyran-3-yl]-phenyl 2,2-dimethylpropanoate (EM-800): A highly potent, specific, and orally active nonsteroidal antiestrogen. J. Med. Chem. 1997, 40, 2117-2122.
23. Sharma, A. P.; Saeed, A.; Durani, S.; Kapil, R. S. Structure-activity relationship of antiestrogens. Phenolic analogues of 2,3-diaryl-2H-1-benzopyrans. J. Med. Chem. 1990, 33, 3222 and references therein.
24. Grese, T. A.; Sluka, J. P.; Bryant, H. U.; Cole, H. W.; Kim, J. R.; Magee, D. E.; Rowley, E. R.; Sato, M. Benzopyran selective estrogen receptor modulators (SERMs): pharmacological effects and structural correlation with raloxifene. Bioorg. Med. Chem. Lett. 1996, 6, 903-908.
25. (a) Boyd, D. B.; Coner, R. D. Stochastic approach to force field evaluations: conformational analysis of raloxifene, a potential new therapeutic agent for post-menopausal osteoporosis. J. Mol. Struct. (THEOCHEM) 1996, 368, 7-15.
26. (b) Kym, P. R.; Anstead, G. M.; Pinney, K. G.; Wilson, S. R.; Katzenellenbogen, J. A. Molecular structures, conformation analysis, and preferential modes of binding of 3-aroyl-2-arylbenzo[b]thiophene estrogen receptor ligands: LY117018 and aryl aside photoaffinity labeling analogs. J. Med. Chem. 1993, 36, 3910-3922.
27. (c) Brzozowski, A. M.; Pike, A. C. W.; Dauter, Z.; Hubbard, R. E.; Monn, T.; Engström, O.; Öhman, L.; Greene, G. L.; Gustafsson, J.-Å.; Carlquist, M. Molecular basis of agonism and antagonism in the oestrogen receptor. Nature 1997, 389, 753-757.
28. Grese, T. A.; Sluka, J. P.; Bryant, H. U.; Cullinan, G, J.; Glasebrook, A. L.; Jones, C. D.; Matsumoto, K.; Palkowitz, A. D.; Sato, M.; Termine, J. D.; Winter, M. A.; Yang, N. N.; Dodge, J. A. Molecular determinants of selectivity in estrogen receptor modulators. Proc. Natl. Acad. Sci. U.S.A. 1997, 94, 14105-14110.
29. 20 command line options of AM1 GRADIENT POLAR GEO-OK HESS=1 EF GNORM=0.01SCFCRT=1D-12 MMOK PRECISE NOINTER and GRAPH. Least squares superimpositions of the stilbene cores were performed using the Insight-II version 95.0.4 (Molecular Simulations Inc., San Diego, CA).
30. By James P. Stewart, Frank J. Seller, Research Laboratory, U.S. Air Force Academy, CO 90940. QCPE No. 455 and references therein.
31. Grese, T. A.; Pennington, L. D. Novel methodology for the synthesis of estrogenic and antiestrogenic isoflav-3-enes. Tetrahedron Lett. 1995, 36, 8913-8916.
32. A portion of this work has previously appeared in communication form: Grese, T. A.; Cole, H. W.; Magee, D. E.; Phillips, D. L.; Shetler, P. K.; Short, L. L.; Glasebrook, A. L.; Bryant, H. U. Conversion of the phytoestrogen coumestrol into a selective estrogen receptor modulator (SERM) by attachment of an amine-containing side chain. Bioorg, Med. Chem. Lett. 1996, 6, 2683-2686.
33. Conley, R. A.; Heindel, N. D. Thianaphthen-2-one chemistry. I. Synthesis of 6H-benzothieno[3,2-c][1]benzopyran-6-ones (11thiacoumestans). J. Org. Chem. 1975, 40, 3169-3173.
34. Ablenas, F. J.; George, B. E.; Maleki, M.; Jain, R.; Hopkinson, A. C.; Lee-Ruff, E. Destabilized carbocations. Nuclear magnetic resonance detection and reactivities of aryl α-thioformamidyl cations. Can. J. Chem. 1987, 65, 1800-1803.
35. Schmid, C. R., unpublished results.
36. Lumma, W. C., Jr.; Dutra, G. A.; Voekker, C. A. Synthesis of two benzothiacyclanones via a novel two-carbon ring expansion of thiolactones with vinyllithium. J. Org. Chem. 1970, 35, 3442-3444.
37. Colvin, E. W.; Martin, J.; Shroot, B. Selective carboalkoxylation of 6-methoxy-2-tetralone. Chem. Ind. (London) 1966, 2130.
38. Sethna, S.; Phadke, R. The Pechman reaction. Org. React. 1953, 7, 1-58.
39. Bindal, R. D.; Durani, S.; Kapil, R. S.; Anand, N. Utility of 4-trimethylsiloxyphenylmagnesium bromide in Grignard reactions. Synthesis 1982, 405.
40. Glasebrook, A. L.; Phillips, D. L.; Sluka, J. P. Multiple binding sites for the anti-estrogen raloxifene (LY156758). J. Bone Miner. Res. 1993, 8 (Suppl. 1), S268. Scholl, S. M.; Huff, K. K.; Lippman, M. E. Antiestrogenic effects of LY117018 in MCF-7 cells. Endocrinology 1983, 113, 611-617. Miller, M. A.; Katzenellenbogen, B. S. Characterization and quantitation of antiestrogen binding sites in estrogen receptor-positive and -negative human breast cancer cell lines. Cancer Res. 1983, 43, 3094-3100.
41. Glasebrook, A. L.; Phillips, D. L.; Sluka, J. P. Multiple binding sites for the anti-estrogen raloxifene (LY156758). J. Bone Miner. Res. 1993, 8 (Suppl. 1), S268. Scholl, S. M.; Huff, K. K.; Lippman, M. E. Antiestrogenic effects of LY117018 in MCF-7 cells. Endocrinology 1983, 113, 611-617. Miller, M. A.; Katzenellenbogen, B. S. Characterization and quantitation of antiestrogen binding sites in estrogen receptor-positive and -negative human breast cancer cell lines. Cancer Res. 1983, 43, 3094-3100.
42. Glasebrook, A. L.; Phillips, D. L.; Sluka, J. P. Multiple binding sites for the anti-estrogen raloxifene (LY156758). J. Bone Miner. Res. 1993, 8 (Suppl. 1), S268. Scholl, S. M.; Huff, K. K.; Lippman, M. E. Antiestrogenic effects of LY117018 in MCF-7 cells. Endocrinology 1983, 113, 611-617. Miller, M. A.; Katzenellenbogen, B. S. Characterization and quantitation of antiestrogen binding sites in estrogen receptor-positive and -negative human breast cancer cell lines. Cancer Res. 1983, 43, 3094-3100.
43. Thompson, E. W.; Reich, R.; Shima, T. B.; Albini, A.; Graf, J.; Martin, G. R.; Dickson, R. B.; Lippman, M. E. Differential growth and invasiveness of MCF-7 breast cancer cells by antiestrogens. Cancer Res. 1988, 48, 6764-6768.
44. Bryant, H. U.; Bendele, A. M.; Magee, D. E.; Cole, H. W.; Spaethe, S. W. Pharmacologic profile of estrogen-induced uterine eosiophilia in the ovariectomized (OVX) rat. Pharmacologist 1992, 34, 194.
45. Wronski, T. J.; Yen, C.-F. The ovariectomized rat as an animal model for postmenopausal bone loss. Cells Mater. 1991, Suppl 1, 69.
46. (a) Fuchs-Young, R.; Magee, D. E.; Cole, H. W.; Short, L.; Glasebrook, A. L.; Rippy, M. K.; Termine, J. D.; Bryant, H. U. Raloxifene is a tissue specific anti-estrogen that blocks tamoxifen or estrogen-stimulated uterotrophic effects. Endocrinology 1995, 135 (Suppl.), 57.
47. (b) Bryant, H. U.; Wilson, P. K.; Adrian, M. D.; Cole, H. W.; Short, L. L.; Dodge, J. A.; Grese, T. A.; Sluka, J. P.; Glasebrook, A. L. Selective estrogen receptor modulators: Pharmacological profile in the rat uterus. J. Soc. Gynecol. Invest. 1996, 3(Suppl), 152A.
48. Grese, T. A.; Cho, S.; Finley, D. R.; Godfrey, A. G.; Jones, C. D.; Lugar, C. W., III.; Martin, M. J.; Matsumoto, K.; Pennington, L. D.; Winter, M. A.; Adrian, M. D.; Cole, H. W.; Magee, D. E.; Phillips, D. L.; Rowley, E. R.; Short, L. L.; Glasebrook, A. L.; Bryant, H. U. Structure-activity relationships of selective estrogen receptor modulators: modifications to the 2-arylbenzothiophene core of raloxifene. J. Med. Chem. 1997, 40, 146-167.
49. Anstead, G. M.; Carlson, K. E.; Katzenellenbogen, J. A. The estradiol pharmacophore: ligand structure-estrogen receptor binding affinity relationships and a model for the receptor binding site. Steroids 1997, 62, 268-303.
50. Dodge, J. A. Presented at the 25th National Medicinal Chemistry Symposium, Ann Arbor, MI, June 1996.
51. On the other hand, in the tamoxifen series, substitution of the dimethylamino group by piperidine does not result in a reduction of uterine stimulation: Robertson, D. W.; Katzenellenbogen, J. A.; Hayes, J. R.; Katzenellenbogen, B. S. J. Med. Chem. 1982, 25, 167-171. Therefore, the presence of cyclic amino functionality appears to be necessary but not sufficient to achieve slectivity with respect to uterine effects (ref 18).
52. Rosati, R. L.; Da Silva Jardine, P.; Cameron, K. O.; Thompson, D. D.; Ke, H. Z.; Toler, S. M.; Brown, T. A.; Pan, L. C.; Ebbinghaus, C. F.; Reinhold, A. R.; Elliot, N. C.; Newhouse, B. N.; Tjoa, C. M.; Sweetnam, P. M.; Cole, M. J.; Arriola, M. W.; Gauthier, J. W.; Crawford, D. T.; Nickerson, D. F.; Pirie, C.; Qi, H.; Simmons, H. A.; Tkalcevic, G. T. Discovery and SAR of a potent nonsteroidal estrogen agonist CP-336,156. J. Bone Miner. Res. 1996, 11 (Suppl. 1), S447.
53. Dodge, J. A.; Lugar, C. W.; Cho, S.; Osborne, J. J.; Phillips, D. L.; Glasebrook, A. L.; Frolik, C. A. Synthesis and estrogen receptor binding affinities of the major human metabolites of raloxifene (LY139481). Bioorg. Med. Chem. Lett. 1997, 7, 993-996, and references therein.
54. (a) McDonnell, D. P.; Clemm, D. L.; Hermann, T.; Goldman, M. E.; Pike, J. W. Analysis of estrogen receptor function in vitro reveals three distinct classes of antiestrogens. Mol. Endocrinol. 1995, 9, 659-669.
55. (b) Klinge, C. M.; Traish, A. M.; Driscoll, M. D.; Hilf, R.; Bambara, R. A. Site-directed estrogen receptor antibodies stabilize 4-hydroxytamoxifen ligand, but not estradiol, and indicate ligand-specific differences in the recognition of estrogen response element DNA in vitro. Steroids 1996, 61, 278-289.
56. For a detailed description of the current understanding of tissue-specific steroid hormone activities, see: Katzenellenbogen, J. A.; O'Malley, B. W.; Katzenellenbogen, B. S. Tripartite steroid hormone receptor pharmacology: Interaction with multiple effector sites as a basis for the cell- and promoter-specific action of these hormones. Mol. Endocrinol. 1996, 10, 119-131.
57. (a) Yang, N. N.; Venugopalan, M.; Hardikar, S.; Glasebrook, A. G. Identification of an estrogen response element activated by metabolites of 17β-estradiol and raloxifene. Science 1996, 273, 1222-1225.
58. (b) Yang, N. N.; Bryant, H. U.; Hardikar, S.; Sato, M.; Galvin, R. J. S.; Glasebrook, A. L.; Termine, J. D. Estrogen and raloxifene stimulate transforming growth factor-β3 gene expression in rat bone: a potential mechanism for estrogen- or raloxifene-mediated bone maintenance. Endocrinology 1996, 137, 2075-2084.
59. Salman, M.; Ray, S.; Anand, N.; Agarwal, A. K.; Singh, M. M.; Setty, B. S.; Kamboj, V. P. Studies in antifertility agents. 50: Stereoselective binding of d- and l-centchromans to estrogen receptors and their antifertility activity. J. Med. Chem. 1986, 29, 1801-1803.
60. Palkowitz, A. D.; Glasebrook, A. L.; Thrasher, K. J.; Hauser, K. L.; Short, L. L.; Phillips, D. L.; Muehl, B. S.; Sato, M.; Shetler, P. K.; Cullinan, G. J.; Pell, T. R.; Bryant, H. U. Discovery and synthesis of [6-hydroxy-3-[4-[2-(1-piperidinyl)ethoxy]phenoxy]-2-(4-hydroxyphenyl)]benzo[b] thiophene: A novel, highly potent, selective estrogen receptor modulator. J. Med. Chem. 1997, 10, 11407-1416.